{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-030831","form_type":"8-K","ticker":"SCNX","cik":"0001382574","company_name":"Scienture Holdings, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.385426+00:00","generated_at":"2026-06-22T05:06:55.063289+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TRxADE Q3 2022: revenue $2.4M (-6% YoY), gross margin 58%, net loss ($0.06)/share, adj EBITDA ($0.4M)","bullets":["Revenue decreased 6% to $2.4M from $2.6M; gross margin improved to 58% from 50%.","Net loss narrowed to ($0.5M) or ($0.06) per share vs ($1.3M) or ($0.16) per share YoY.","Adjusted EBITDA turned negative at ($0.4M) compared to positive $0.7M in Q3 2021.","Added 291 new registered members in Q3; total ~14,100+; Bonum Health signed telemedicine deal with ShopRite.","Bonum Health entered distribution agreements with multiple insurance brokerage firms for employer groups in Oct 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-030831","json":"https://secwatch.observer/filing/0001493152-22-030831.json","markdown":"https://secwatch.observer/filing/0001493152-22-030831.md","text":"https://secwatch.observer/filing/0001493152-22-030831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382574/000149315222030831/0001493152-22-030831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382574/000149315222030831/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:06:55.063289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a919b9b5081e5ea45da8b9acaaac74bab60e8968","claim":"Scienture Holdings, Inc. reported for the three and nine months ended September 30, 2022 results: revenue $2.4 million, net income ($0.5) million, EPS ($0.06) per basic and diluted share.","evidence_excerpt":"growth opportunities.” Third Quarter 2022 Financial Summary Consolidated revenues for the third quarter of 2022 compared to the third quarter of 2021, decreased 6% to $2.4 million, compared to $2.6 million, respectively. The consolidated decrease in revenue, is driven by decreases in revenue attributed to our TRxADE Prime and Community Specialty Pharmacy","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382574/000149315222030831/0001493152-22-030831-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the three and nine months ended September 30, 2022"},{"label":"Revenue","value":"$2.4 million"},{"label":"Net income","value":"($0.5) million"},{"label":"EPS","value":"($0.06) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}